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Abstract
The prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency is high in Asia. An ex vivo study was conducted to
elucidate the association of G6PD deficiency and dengue virus (DENV) infection when many Asian countries are hyper-
endemic. Human monocytes from peripheral mononuclear cells collected from 12 G6PD-deficient patients and 24 age-
matched controls were infected with one of two DENV serotype 2 (DENV-2) strains–the New Guinea C strain (from a case of
dengue fever) or the 16681 strain (from a case of dengue hemorrhagic fever) with a multiplicity of infection of 0.1. The
infectivity of DENV-2 in human monocytes was analyzed by flow cytometry. Experimental results indicated that the
monocytes of G6PD-deficient patients exhibited a greater levels of infection with DENV-2 New Guinea C strain than did
those in healthy controls [mean6SD:33.6%63.5 (27.2%,39.2%) vs 20.3%66.2 (8.0%,30.4%), P,0.01]. Similar observations
were made of infection with the DENV-2 16681 strain [40.9%63.9 (35.1%,48.9%) vs 27.4%67.1 (12.3%,37.1%), P,0.01].
To our knowledge, this study demonstrates for the first time higher infection of human monocytes in G6PD patients with
the dengue virus, which may be important in increasing epidemiological transmission and perhaps with the potential to
develop more severe cases pathogenically.
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Introduction
Dengue virus (DENV), a member of the Flaviviridae family, has
four serotypes of DENV-DENV-1, DENV-2, DENV-3 and
DENV-4. Clinical manifestations of DENV infection range from
asymptomatic to dengue fever (DF) and dengue hemorrhagic fever/
dengue shock syndrome (DHF/DSS). About 100 million dengue
cases occur aroundthe world annually [1]. DF and DHF/DSS have
emerged as the most important mosquito-borne viral diseases in
tropical and subtropical countries, particularly in urban areas. DHF
has expanded concomitantly in many geographical regions [2,3].
However, the underlying mechanisms of DHF remain unknown.
The predominant target cells of DENV that are infected in
humans have been identified as mononuclear phagocytes,
monocytes, macrophage and dendritic cells [4–7]. These cells
are responsible for disseminating the virus after its initial entry
following the infection from mosquito bites. Since monocytes and
macrophages are active phagocytic cells with cytoplasmic
lysosomal components that can eliminate microorganisms [8],
the interaction of the DENV with monocytes and macrophages
may have detrimental effects on both virus and cells. Soluble
mediators that are released from dengue virus-infected mono-
cytes/macrophages strongly affect the biological characteristics of
endothelial cells and the hematopoietic cell population, indicating
that the interactions between dengue virus and monocytes/
macrophages are important in the pathogenesis of DHF/DSS.
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in
the cytoplasm of all human cells [9]. G6PD deficiency that
involves more than 300 allelic variants is one of the most inherited
human disorders, as more than 400 million people are affected
globally [10,11]. The frequency of G6PD deficiency differs
substantially among populations. About 7.5% of the global
population carries one or two genes for G6PD deficiency. This
proportion actually ranges from a maximum of 35% in parts of
Africa, to 0.1% in Japan and parts of Europe [11]. High
frequencies (6.0,10.8%) of G6PD deficiency are also evident in
Southeast Asia [12]. The overall prevalence of this deficiency is
2.1% in Taiwan [13]. The clinical manifestations of G6PD
deficiency are neonatal jaundice, favism and acute haemolytic
anemia [11]. Infection-induced hemolysis, involving many micro-
bial agents, may be a common cause of clinically significant
hemolytic anemia [14,15] in G6PD-deficient patients, but its
mechanism is unclear. Several studies have indicated that the
abnormal function of leucocytes increases susceptibility to
infection, such as by hepatitis A, in G6PD-deficient patients,
causing more severe initial clinical presentations [9,14,16–18].
The association between G6PD deficiency and recurrent bacterial
infection in children has been described elsewhere [18,19]. A
higher percentage of G6PD-deficient patients than non-G6PD-
deficient patients has been associated with DHF/DSS (19.1%) in
Thailand [20]. Epidemics of dengue in Taiwan have occurred
frequently when imported cases have not been properly controlled
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monocytes from peripheral blood mononuclear cells (PBMC) of
G6PD-deficient patients were more likely to be infected, regardless
of the dengue virus strain. The results revealed that monocytes
from PBMC of G6PD-deficient patients were more susceptible to
DENV-2 infection with higher replication ability than those from
healthy controls
Results
Growth curve of DENV-2 in human monocytes of healthy
controls
PBMC monocytes from healthy controls obtained using the
MACS monocyte isolation kit were infected with DENV-2 (New
Guinea C or 16681 strain) at an MOI of 0.1. After those cells had
been incubated in 5% CO2 at 37uC for five days, the infected
monocytes and cell culture supernatants were harvested at various
times post-infection. The quantitative measures of DENV-2 viral
infection in monocytes were the percentage of cells to be infected,
quantified by flow cytometry and the viral yields in the
supernatant, determined by plaque assay (Figure 1). Flow
cytometry indicated that human monocytes from healthy controls
could be infected with DENV-2 and that the infections peaked on
the third day post-infection for both New Guinea C and 16681
strains of DENV-2 (16681: 32.1% vs New Guinea C: 24.2% ).
However, the percentages of human monocytes from the healthy
controls that were infected with DENV-2 16681 strain exceeded
that of those with DENV-2 New Guinea C strain from day one to
day five post-infections. The infections of monocytes with DENV
were also detected with indirect immunofluorescence stain
(Figure 2A and 2B). Such infections were further verified by the
virus yields of DENV-2 in the supernatants that are shown in
Figure 1. Again, human monocytes infected with either New
Guinea C or 16681 strains of DENV-2 exhibited similar growth
patterns. The DENV-2 viral yield in cell culture supernatants also
peaked three days post-infection and the viral yields of human
monocytes from healthy controls that were infected with DENV-2
16681 also exceeded those that were infected with New Guinea C
infection (2.1610
3 PFU/ml vs. 1.3610
3 PFU/ml). Restated, the
viral yields from the supernatants of human monocytes from the
healthy controls, measured by plaque assay, were very similar to
the percentages of cells that were infected, as measured by flow
cytometry. Based on this high correlation between the results of
the two methods, flow cytometry was used to measure DENV-2
infectivity in infected monocytes in the following experiments.
Ex vivo infection of DENV-2 in human monocytes from
G6PD-deficient patients and healthy controls
Monocytes from G6PD-deficient patients and healthy controls
were collected and separately infected with DENV-2. The infected
cells were harvested and the infection for DENV-2 in human
moncytes was analyzed by flow cytometry. Figures 3A and 3B plot
the results obtained using the monocytes from one healthy donor
infected with DENV-2 New Guinea C and 16681 strains,
respectively. The percentage of positive cells was slightly higher
in DENV-2 16681-infected cells (26.1%) than in DENV-2 New
Guinea C-infected cells (20.1%). Figures 4A and 4B plot the results
obtained using human PBMC monocytes from one G6PD-
deficient patient who was infected with both of the aforementioned
strains of DENV-2. The percentage of cells that were infected with
the 16681 strain as well as the percentage of cells that were
infected with the New Guinea C strains both exceeded the
respective percentages of cells from the healthy controls that were
infected (42.8% vs 26.1%, 32.6% vs 20.1%, respectively).
PBMC monocytes from 12 G6PD-deficient patients and 24
healthy controls were collected and infected with both strains of
DENV-2 to investigate whether the above results concerning
Figure 1. Growth of DENV-2 in human monocytes from one
healthy control. Monocytes were infected with DENV-2 New Guinea C
(NGC) and 16681 strains at an MOI of 0.1 for five days. The virus titer in
the cell culture supernatants were analyzed by plaque assay (—) and
the intracellular replication of virus in the infected cells were detected
by flow cytometry ( ---- ).
doi:10.1371/journal.pone.0001557.g001
Figure 2. Detection of DENV in infected monocytes from one healthy control by using immunofluorescence staining. (A) Mock-
infected cells. (B) DENV-2 infected monocytes. Monocytes were infected by DENV-2 New Guinea C strain at an MOI of 0.1 and then cultured for three
days. Evans blue was added as a counter-stain to differentiate non-infected cells (shown by red color) from the dengue virus-positive infected cells
(shown by green color).
doi:10.1371/journal.pone.0001557.g002
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deficient patients than in those of healthy controls apply various
G6PD patients. The results indicated that the mean percentage of
human monocytes that were infected with New Guinea C in
G6PD-deficient patients statistically significantly exceeded the
percentage infection of those of the healthy controls [G6PD-
deficient patients: 33.663.5% (27.2%,39.2%) versus healthy
controls: 20.366.2% (8.0%,30.4%), P,0.01]. A similarly was
obtained from cells that were infected with 16681. The mean
percentages of human monocytes in G6PD-deficient patients
and of those in healthy controls that were infected with DENV-2
16681 were 40.963.9% (35.1%,48.9%) and 27.467.1%
(12.3%,37.1%), respectively (P,0.01). All of the 12 G6PD-
deficient patients yielded similar results-with higher percentages of
infected monocytes than were found in the 24 healthy donors
(Figure 5). Comparing the infection capability of the two
DENV-2 stains clearly reveals that more infected cells were
present in 16681 than in New Guinea C-infected monocytes
(P,0.05) that were collected from either G6PD-deficient patients
or healthy controls.
Detection of anti-DENV antibodies in G6PD-deficient
patients using PRNT
Severe DENV infections have commonly observed in patients
with secondary dengue viral infection in many South East Asian
countries [1–3]. Plasma samples from all G6PD-deficient patients
and healthy controls were tested in the presence of four DENV
serotype-specific antibodies using PRNT to clarify whether the
higher infection capability of DENV-2 in the monocytes of G6PD-
deficient patients was caused by the secondary dengue viral
infection. None of the four serotype specific DENV antibodies was
detected in any of the 12 G6PD-deficient patients or 24 healthy
controls. The results revealed that the higher infection percentage
of DENV-2 in the monocytes of G6PD deficient-patients than in
healthy people was not associated with prior DENV infections.
Discussion
One of the important virological characteristics of severe
dengue hemorrhagic fever (DHF) patients is elevated viral load
[22]. The association of G6PD deficiency and microbial infections,
Figure 3. Flow cytometry analysis of DENV-2 infected human monocytes from one healthy control. New Guinea C strain (A) and 16681
strain (B) of DENV-2 were infected at an MOI of 0.1 and their infection levels on day three post-infection were measured by flow cytometry. Black:
Percent DENV-2 infected cells. White: Percent mock-infected cells (background)
doi:10.1371/journal.pone.0001557.g003
Figure 4. Flow cytometry analysis of DENV-2 infected human monocytes from one G6PD-deficient patient. Cells infected with New
Guinea C strain (A) and 16681 strain (B) at an MOI of 0.1 and observed on day three post-infection. Black: Percent DENV-2 infected cells. White:
Percent mock-infected cells (background)
doi:10.1371/journal.pone.0001557.g004
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first work to demonstrate clearly that the PBMC monocytes
obtained from G6PD-deficient patients, using an ex vivo culture
system, were more easily infected with the two DENV-2 strains-(1)
the New Guinea C strain from the DF patient or (2) the 16681
strain from the DHF patient than with those from healthy
controls. This finding suggests that the high capability for DENV
infection in human monocytes in vivo may increase viral yield,
which may create more problems in the efficient clearance of the
virus and thus increase the likelihood of a severe clinical outcome
of dengue in G6PD-deficient patients. This suggestion is consistent
with our earlier finding that DHF patients had higher viral loads
even during the defervescence stage [22]. In Taiwan, the
prevalence of G6PD deficiency in general population is about
2.1% [13]. When G6PD-deficient patients are infected with
DENV, their higher viral load may increase the probability of
transmission of the infection to others via infected mosquitoes, if
mosquito breeding sites are not properly environmentally
controlled [23]. In Thailand, the prevalence of G6PD deficiency
in the general population is approximately 11% [20], explaining
the higher prevalence of G6PD deficiency in DHF patients
(19.1%) even though the study that supported this conclusion did
not use a control group [20]. This conclusion also supports the
public health implication that more efficient prevention and
control of dengue is required in areas in which many G6PD-
deficient patients live.
The mechanism of increased infection with DENV-2 in
monocytes from G6PD-deficient patients remains unclear. The
mutation in G6PD probably leads to granulocyte dysfunction,
preventing the clearing of the infection at the first line of defense
and thereby increasing susceptibility to DENV [24]. In fact, severe
G6PD deficiency impairs respiratory burst activity and results in
the generation of the less reactive oxygen species (ROS, including
super-oxide anion, hydrogen peroxide and hydroxyl radical),
causing abnormal function of the neutrophils and monocytes, as in
HIV infection in vitro [25] and in ROS-deficient mice, which are
extremely susceptible to infection [26]. Interestingly, ROS
inhibited the RNA replication of hepatitis C virus, a member of
the same family (Flaviviridae) as DENV, in human hepatoma cells
[27]. Therefore, the greater infection of DENV in human
monocytes from G6PD-deficient patients may be associated with
the low activity of ROS in monocytes, which exhibit reduced
activity for eliminating the invaded DENV-2 in infected cells.
The importance of host factors, such as human leukocyte antigen
(HLA) and dendritic cell–specific intercellular adhesion molecule-3
grabbing nonintegrin (DC-SIGN) genes, in the pathogenesis of
DENV infections has been documented [28,29]. This study
demonstrates that more attention should be paid to another host
genetic factor (G6PD) and to co-morbidity on both individual and
community levels when DENV infection has occurred. Effort must
be made to conduct an international comparative case-control study
in DHF endemic or hyper-endemic countries/areas with a range of
prevalence of G6PD deficiency, by measuring the viral load and
immunity in G6PD-deficient patients versus controls during the
infecting process at various times following infection, as well as
associated clinical outcomes. The results provide a new direction for




Twelve male patients with G6PD deficiency and 24 (18 male
and eight female) age-matched healthy controls (with mean ages of
32.167.3 and 29.365.1 years respectively, P=0.2), as that shown
in Table 1, participated in the study. G6PD deficiency was defined
as enzyme activity of less than the reference value (4 IU/gHb), as
measured using the ELISA method [30]. The mean G6PD activity
of the G6PD-deficient patients (0.560.9 IU/gHb) was significant-
ly less than that of the healthy controls (12.462.6 IU/gHb,
P,0.01) (Table 1). All the 12 G6PD deficient male patients were
confirmed to be G6PD deficient using the molecular-biology
method as that has been described previously [30]: seven subjects
carrying single-point mutation at nucleotide 1376 (G to T,
Arg459Leu), four at nucleotide 1388 (G to A, Arg463His), and
one at nucleotide 493 (A to G, Asn165Asp), respectively. All
participants had written informed consent before their blood
samples were withdrawn for further study. The protocol was also
passed by the Ethical Committee of the College of Public Health
at National Taiwan University. All 12 G6PD-deficient patients
and the 21 healthy controls lived in northern Taiwan, with only
sporadic dengue cases, but the three volunteers lived in southern
Taiwan, where dengue epidemics occur more often.
Viruses
Two DENV-2 strains, the New Guinea C strain, isolated from a
patient with dengue fever, and the 16681 strain, isolated from a
patient with DHF, were grown from mosquito C6/36 cells in a
growth medium of 50% Mitsumashi and Maramorsch Insect
Medium (MMIM; Sigma, Saint Louis, Missouri, United States)
Figure 5. Box plot for comparison of the ex vivo infection
percentages of DENV-2 (New Guinea C and 16681 strain) in
monocytes of PBMC obtained from 12 G6PD-deficient patients
and 24 healthy controls.
doi:10.1371/journal.pone.0001557.g005
Table 1. Gender and age distributions of study populations
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(DMEM; GIBCO, Grand Island, NY, United States) plus 2% fetal
bovine serum (FBS) at 28uC for 7 to 9 days. The viruses in the
supernatants were harvested and stored at 280uC. The titers of
the viruses were titrated in baby hamster kidney (BHK-21) cells
using plaque assay.
Isolation of human monocytes and cell culture
PBMCs from 10 ml peripheral blood samples from both G6PD-
deficient patients and healthy controls were isolated in EDTA-
containing tubes by density centrifugation with Ficoll-Hypaque.
The mononuclear leukocytes recovered from the interface were
washed twice by phosphate-buffered saline (PBS, pH 7.2) and
suspended in RPMI 1640 medium with 10% FBS and penicillin/
streptomycin [31]. Human monocytes were purified by depleting
non-monocytes using a MACSH kit system (Miltenyi Biotec GmbH,
Gladbach, Germany) by negative selection. Non-monocytes were
indirectly magnetically labeled with a cocktail of biotin-conjugated
mouse monoclonal antibodies against CD3, CD7, CD16, CD19,
CD56,CD123 and CD235a,asprimarylabeling reagents,andanti-
biotin monoclonal antibodies that were conjugated with MicroBe-
ads, as secondary labeling reagents. The unlabeled monocytes
passed through the column. The purity of these human monocytes
(ranged from 91.4%–99.9%). The purified human monocytes were
cultured in RPMI 1640 (GIBCO, Grand Island, NY, United States)
medium with 10% FBS and 1% penicillin-streptomycin, as well as
antimycotic (GIBCO, Grand Island, NY, United States), and
incubated at 37uCi n5 %C O 2 incubator.
Ex vivo infection of DENV-2
Human monocytes were each infected with one of the two
strains of DENV-2, New Guinea C (DF strain) and 16681 (DHF
strain), at a multiplicity of infection (MOI) of 0.1. Following
absorption at 37uC for 3 hours, the monocytes were washed twice
and suspended with medium. The infected monocytes were added
in equal amounts to six-well plates, incubated at 37uC5 %C O 2 for
five days, and then quantified at various times post-infection by
flow cytometry. Mock-infected cells were added to another plate as
controls and were run simultaneously with the infected group to
improve gating and the precision of measurement.
Immunofluorescence stain
The infected and mock-infected monocytes were harvested and
fixed on slides using cold acetone for 10 minutes. The monoclonal
antibody (MAb) against DENV-2 (3H5) [32] was added to the
fixed cells and then incubated at 37uC for 30 minutes. After the
cells were washed, goat anti-mouse antibody conjugated with
fluorescein isothiocyanate (FITC) (Kirkegaard & Perry Laborato-
ries, United States) was added and incubated for another
30 minutes at 37uC. The results were observed under an
immunofluorescence microscope for double confirmation before
the samples were analyzed by flow cytometry.
Flow cytometry
The human monocytes that were infected with the two DENV-2
strains (New Guinea C or 16681) and the mock infected monocytes
were removed from the six-well plates, and washed twice with PBS
(pH 7.2). The harvested cells were fixed and permeabilized with 4%
paraformaldehyde and 0.2% sarponin. The permeabilized mono-
cytes were washed and incubated with CD14-PE MAb (Becton
Dickinson, San Jose ´, CA, United States) for 30 minutes at 4–8uCi n
the dark. Another mouse MAb (3H5) against DENV-2 was used to
quantify the infected cells by incubating it with the tested human
monocytes for 30 minutes at 4–8uC. The cells were then washed and
incubated with FITC-labeled affinity-purified goat anti-mouse IgG
(Kirkegaard & Perry Laboratories, United States) for 30 minutes at
room temperature. Following incubation, the cells were washed twice
in PBS (pH 7.2) and then analyzed using a FACScan flow cytometer
(Becton Dickinson FACSCalibur System, United States). The mock-
infected monocytes were run in parallel and served as negative
controls. At least 10,000 cells were analyzed using a flow cytometer.
Data were analyzed using Cell Quest software (Becton Dickinson,
San Jose ´, CA, United States). The percentage of positive cells and the
average fluorescence intensities were determined from FITC
fluorescence histograms using a region that was defined based on
the analysis of the mock-infected control cells).
Plaque Reduction Neutralization Test (PRNT)
PRNT was performed to detect the serotypes of DENV
antibodies that had been infected in the past, from plasma
samples collected from G6PD-deficient patients, with reference to
healthy controls. Four prototype DENVs (DENV-1:Hawaii,
DENV-2:New Guinea C, DENV-3:H87 and DENV-4:H241, all
obtained from Dr. Duane Gubler at the U.S. Centers for Disease
Control and Prevention, Atlanta, Georgia. United States) were
used in PRNT. Briefly, the plasma was inactivated at 56uC for
30 minutes. The four-fold diluted (1:10 ,1:640) plasma and
viruses were mixed well in equal amounts in the 96-well plates and
incubated at 4uC overnight. The mixture was added to the BHK-
21 cells that had been grown in the 24-well plates and incubated at
37uC5 %C O 2 for one week. After the cells were fixed with 5%
crystal violet, the plaques were counted. The serotiters of the
neutralization antibody were determined using a 75% reduction
from the number of plaques of the virus control as a cut-off point.
The virus titer was expressed as the number of plaques that formed
unit per ml (PFU/ml).
Statistical Tests
The Student’s T test was used to analyze the differences in means
of percentages of DENV-2 positive infected monocytes between the
patients with G6PD and age-matched healthy controls.
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